Back to News
Market Impact: 0.22
MiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell Therapy
Source: GlobeNewswire
Healthcare & BiotechTechnology & Innovation
The clinical-stage agenT-797 invariant natural killer T-cell platform was selected as the therapeutic cell platform for ARPA-H's BoSS program. The initiative aims to advance living medicines from cryogenic storage requirements toward room-temperature stability, potentially improving the deployment and accessibility of cell therapies.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
INKT0.65
More News
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Why is Kioxia stock rallying today?
- We're raising our Micron price target after an incredible quarter and robust guidance
- Micron Forecast Tops Estimates on Booming AI Memory Demand